Kabir Nath is recorded as CEO and Board Member at COMPASS Pathways plc (CMPS). The newest filing on record that lists Kabir Nath as CEO and Board Member at COMPASS Pathways plc (CMPS) is dated April 15, 2026. COMPASS Pathways plc reported in an 8-K filed July 19, 2022 that Kabir Nath was appointed Class II director, effective August 1, 2022. COMPASS Pathways plc reported in an 8-K filed July 19, 2022 that Kabir Nath was appointed chief executive officer, effective August 1, 2022. Kabir Nath has spoken on 15 earnings calls and 2 other investor events across 1 company, most recently for COMPASS Pathways plc on September 16, 2026. COMPASS Pathways plc is classified in the Medical Care Facilities industry within the Healthcare sector. Other leadership on record at COMPASS Pathways plc includes David Norton (Chairman and Board Member), George Goldsmith (Chairman), Gino Santini (Chairman and Board Member) and 7 others.
“Mr. Nath will also be appointed as a member of the board of directors as a Class II director effective as of August 1, 2022.”
COMPASS Pathways plc Form 8-K, filed July 19, 2022
· Read the filing
“On July 19, 2022, COMPASS Pathways plc (the “Company”) announced that its board of directors has appointed Kabir Nath as the Company’s chief executive officer effective August 1, 2022.”
COMPASS Pathways plc Form 8-K, filed July 19, 2022
· Read the filing
Kabir Nath on recent calls
“And just our own disclosures, I will be making forward-looking statements. We will be kind of, and please refer to our various risk factors.”
“Just a reminder, we will be making some forward-looking statements here, so you should refer to our many risk factors in our various findings. We have had breakthrough designations since 2018, based on some of the early work and the resurgence of interest in psychedelics in 2010 onwards.”
“It has been a very exciting and productive quarter for Compass. The company continues to lead the way in psychedelic science, validated by the confirmation of a rolling NDA submission and review, and the award of a Commissioner's National Priority Voucher, or CNPB.”
“Our first phase three trial, Comp005, demonstrated a highly statistically significant result for the primary endpoint in June, which was an important de-risking event for the company.”
